Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: A population-based study from the national prostate cancer register of Sweden

Scandinavian Journal of Urology and Nephrology

Volumn 44, Issue 6, 2010, Pages 384-390

  Bratt, Ola ^a   Berglund, Anders ^b,c   Adolfsson, Jan ^c   Johansson, Jan Erik ^d   Trönblom, Magnus ^e   Stattin, Pär ^f  

^a HELSINGBORG HOSPITAL   (Sweden)

^b Regional Oncologic Centre   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e Sdersjukhuset   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

Epidemiology; Incidence; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; GLEASON SCORE; HUMAN; LOWER URINARY TRACT SYMPTOM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; SWEDEN;

EID: 78649308573     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2010.498793     Document Type: Article

References (19)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
2. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate Cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56:584-91.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
5. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-59.
7. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
8. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659-64.
9. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456-77.
10. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27-33.
11. Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
12. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
13. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Gleason score 7 screendetected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 2009;103:1472-7.
14. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med 2008;149:192-9.
15. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
16. Hughes AM, Sladden MJ, Hirst GH, Ward JE. Community study of uncomplicated lower urinary tract symptoms among male Italian immigrants in Sydney, Australia. Eur Urol 2000;37:191-8.
17. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst 2009;101:1216-20.
18. Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt O, et al. Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005;39:372-9.
19. Abrahamsson PA, Artibani W, Chapple CR, Wirth M. European Association of Urology position statement on screening for prostate cancer. Eur Urol 2009;56:270-1.